AstraZeneca, Biovail enter into agreement for Zoladex

Share this article:
AstraZeneca and Biovail have entered into an agreement in which Biovail's specialty sales force will promote AstraZeneca's Zoladex (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the US and Puerto Rico. Financial terms of the deal were not disclosed. Biovail's 85-member specialty sales force currently promotes Zovirax cream and ointment to specialists and selected primary-care physicians in the US. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.